Allgayer H, Härlin M, Weinzierl M, Bircher J, Paumgartner G
Dtsch Med Wochenschr. 1984 Oct 5;109(40):1521-4. doi: 10.1055/s-2008-1069405.
Eight patients with inoperable echinococcosis, four each with the cystic or alveolar form, had received mebendazole (Vermox) at a daily dose of 1.5 g for an average of 27 months. In six patients with clinical symptoms the number of fever attacks fell by 60% and of hospital admissions by 54%, cholangitic and/or icteric attacks disappearing completely. Two patients had no recognizable symptoms, either before or after treatment. One woman with multilocular disease died of bleeding from esophageal varices. The immunological and morphological findings did not reveal any relationship to the clinical course. Apart from reversible leukopenia in one patient there were no serious side effects. These observations indicate a satisfactory effect of long-term treatment of inoperable echinococcosis with mebendazole.
8例无法手术的棘球蚴病患者,其中4例为囊型,4例为泡型,接受了甲苯达唑(肠虫清)治疗,日剂量为1.5 g,平均治疗27个月。6例有临床症状的患者发热发作次数减少了60%,住院次数减少了54%,胆管炎和/或黄疸发作完全消失。2例患者治疗前后均无明显症状。1例患有多房性疾病的女性死于食管静脉曲张出血。免疫学和形态学检查结果与临床病程无任何关联。除1例患者出现可逆性白细胞减少外,无严重副作用。这些观察结果表明甲苯达唑长期治疗无法手术的棘球蚴病效果良好。